# Emodin (from Rheum spp., Aloe vera, Polygonum multiflorum)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/emodin-from-rheum-spp-aloe-vera-polygonum-multiflorum
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** 1,3,8-trihydroxy-6-methylanthraquinone, Frangula-emodin, Rheum emodin, 3-methylchrysazin, CI 75440

## Overview

Emodin is a 1,3,8-trihydroxy-6-methylanthraquinone that exerts anticancer and [anti-inflammatory](/ingredients/condition/inflammation) effects by inhibiting mTOR/HIF-1α/VEGF signaling, inducing [mitochondrial](/ingredients/condition/energy) apoptosis via BCL-2 downregulation and caspase-3 activation, and arresting the cell cycle at G2/M phase. Preclinical data demonstrate antitumor activity at 20–100 µM in hepatocellular (HepG2), colorectal (DLD-1, COLO-201), and prostate (PC3) cancer cell lines, and anti-inflammatory efficacy at 20–40 mg/kg in rodent acute lung injury models, though no large human clinical trials have yet confirmed these effects.

## Health Benefits

- **Anticancer Activity**: Emodin promotes apoptosis in multiple cancer cell lines by downregulating the anti-apoptotic protein BCL-2, upregulating pro-apoptotic BAX, and activating caspase-3, inducing [mitochondrial](/ingredients/condition/energy) dysfunction at concentrations of 20–100 µM in HepG2, DLD-1, and COLO-201 cells.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Effects**: By inhibiting the mTOR/HIF-1α/VEGF signaling axis, emodin reduces inflammatory cytokine production and vascular permeability; in rodent models of LPS-induced acute lung injury, doses of 20–40 mg/kg significantly attenuated lung histopathology.
- **Laxative and Gastrointestinal Function**: As an anthraquinone glycoside precursor, emodin stimulates colonic peristalsis by irritating the intestinal mucosa and increasing fluid secretion, underpinning the traditional use of rhubarb and aloe as laxatives in both Ayurvedic and Traditional Chinese Medicine.
- **Suppression of Tumor Invasion and Metastasis**: Emodin upregulates miR-1271 and downregulates transcription factors ZEB1 and TWIST1 to suppress epithelial-mesenchymal transition (EMT) at 20–40 µM in SW1990 pancreatic cancer cells, and inhibits MMP-2/9 via p38MAPK activation at 5–200 µM in MHCC-97H hepatocellular carcinoma cells.
- **[Immunomodulat](/ingredients/condition/immune-support)ion**: Emodin expands regulatory T cell populations (CD4+FoxP3+ and CD8+CD122+) and blocks dendritic cell maturation through mTOR inhibition, demonstrating immunosuppressive effects at 10 mg/kg in murine skin allograft transplant models relevant to autoimmune and transplant medicine.
- **Antibacterial Activity**: Emodin and its halogenated derivative 2-iodoemodin exhibit antibacterial effects against gram-positive organisms, with 2-iodoemodin achieving MIC values of 1–2 µg/ml; the mechanism involves [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) generation and [autophagy](/ingredients/condition/longevity) suppression within bacterial cells.
- **Cell Cycle Arrest**: Emodin induces G2/M phase arrest in prostate cancer (PC3) cells via Notch signaling inhibition at 10–80 µg/ml, and restores p53 tumor suppressor function through autophagy modulation at 15–20 µM in A549 lung adenocarcinoma cells, halting aberrant proliferation.

## Mechanism of Action

Emodin (1,3,8-trihydroxy-6-methylanthraquinone) modulates cancer cell survival primarily by suppressing the mTOR/HIF-1α/VEGF axis, reducing hypoxia-driven angiogenesis and [inflammatory](/ingredients/condition/inflammation) vascular permeability, while simultaneously triggering intrinsic apoptosis through [mitochondrial](/ingredients/condition/energy) membrane depolarization, BCL-2 downregulation, BAX upregulation, and sequential activation of caspase-9 and caspase-3. At the cell cycle level, emodin arrests cells in G2/M phase by inhibiting Notch signaling and restoring p53 activity through [autophagy](/ingredients/condition/longevity)-mediated degradation of negative p53 regulators, thereby preventing mitotic entry in transformed cells. Emodin also attenuates metastatic potential by upregulating the tumor-suppressor microRNA miR-1271, which represses EMT transcription factors ZEB1 and TWIST1, and by activating p38MAPK to suppress matrix metalloproteinases MMP-2 and MMP-9 that degrade extracellular matrix barriers. Its [immunomodulatory](/ingredients/condition/immune-support) action is mediated through mTOR inhibition in dendritic cells, blocking their maturation and antigen-presenting capacity, while simultaneously promoting CD4+FoxP3+ and CD8+CD122+ regulatory T cell expansion to dampen alloimmune and autoimmune responses.

## Clinical Summary

No published human clinical trials with defined sample sizes, randomization, or reported effect sizes have specifically investigated purified emodin for anticancer or [anti-inflammatory](/ingredients/condition/inflammation) indications, making a formal clinical summary impossible based on current evidence. Pharmacokinetic data from human volunteer studies with emodin-containing plant extracts indicate that emodin itself is largely undetectable in plasma after oral administration, while its bacterial metabolite rhein appears in a biphasic pattern peaking at 3–5 hours and 10–11 hours post-dose at concentrations of 150–160 ng/ml, suggesting extensive first-pass and colonic [metabolism](/ingredients/condition/weight-management). The laxative effects of rhubarb and aloe vera extracts containing emodin have broader clinical documentation in traditional medicine contexts, but these studies rarely isolate emodin as the sole active constituent. Until adequately powered phase I/II human trials establish safe dose ranges, pharmacokinetic profiles, and measurable clinical endpoints, emodin's therapeutic potential in humans remains speculative despite compelling preclinical mechanistic data.

## Nutritional Profile

Emodin is a pure phytochemical compound (molecular formula C₁₅H₁₀O₅; molecular weight 270.24 g/mol) rather than a whole-food nutrient source, and thus lacks macronutrient or micronutrient content in the conventional dietary sense. As a polyphenolic anthraquinone, it belongs to the broader class of plant secondary metabolites and is present in rhubarb root at concentrations detectable in the 10–100 µg/ml range in standardized extracts, co-occurring with structurally related anthraquinones (aloe-emodin, rhein, chrysophanol, physcion), anthrone glycosides, and stilbenes such as resveratrol in Rheum species. Oral bioavailability of intact emodin is low; plasma concentrations after ingestion of plant extracts are often below detection limits, with the primary circulating metabolite being rhein (formed by colonic bacterial oxidation), which reaches peak plasma levels of 150–160 ng/ml in a biphasic curve at 3–5 hours and 10–11 hours post-dose. Lipophilicity (logP approximately 1.5–2.0) contributes to variable gastrointestinal absorption, and first-pass hepatic [metabolism](/ingredients/condition/weight-management) further limits systemic exposure to the parent compound.

## Dosage & Preparation

- **Plant Extract (Rhubarb Root)**: Traditional preparations use dried and powdered rhizome at 3–9 g per day in decoction form as used in Traditional Chinese Medicine for laxative and [anti-inflammatory](/ingredients/condition/inflammation) purposes; emodin content varies by species and processing.
- **Aloe Latex**: Whole-leaf aloe preparations containing emodin and aloe-emodin were historically used as laxatives at doses equivalent to 20–30 mg anthraquinone glycosides per day; isolated emodin supplementation is not standardized for human use.
- **Standardized Extracts**: Analytical standardization of emodin-containing extracts is performed by spectrophotometry at 437 nm in methanol; Beer's law is obeyed in the 10–100 µg/ml range with a limit of quantification of 1.25 µg/ml and detection at 0.41 µg/ml per validated ICH-compliant methods.
- **Preclinical Reference Doses (Animal)**: Anti-inflammatory and anticancer effects observed at 10–80 mg/kg body weight in mice and rats; these have not been validated or converted to established human equivalent doses (HED).
- **In Vitro Reference Concentrations**: Bioactive effects documented at 5–100 µM in cell culture; 20 µM was non-toxic to normal HL-60N1 cells in comparative studies, suggesting a potential therapeutic window that has not yet been confirmed in humans.
- **Timing**: No human clinical timing data available; traditional laxative preparations from rhubarb are typically taken at bedtime to allow overnight colonic transit time.

## Safety & Drug Interactions

Emodin demonstrated no observable organ toxicity or pathophysiological changes in rodents at doses of 20–80 mg/kg administered for up to 12 weeks, and 20 µM concentrations were non-cytotoxic to normal hematopoietic cells (HL-60N1) in vitro; however, the safety profile in humans has not been formally established through clinical trials. A significant genotoxicity concern exists for anthraquinone compounds as a class — regulatory agencies including the European Medicines Agency have raised warnings about the potential mutagenic and carcinogenic risk of anthraquinone-containing herbal products with long-term use, and emodin itself has shown genotoxic potential in some in vitro assays, though this has not been definitively resolved. Drug interactions have not been characterized in human pharmacokinetic studies, but theoretical interactions exist with anticoagulants (anthraquinones may affect intestinal transit and drug absorption), immunosuppressants (due to emodin's mTOR-inhibitory [immunomodulatory](/ingredients/condition/immune-support) effects), and nephrotoxic agents (given that anthraquinone metabolites are renally cleared and some have shown nephrotoxic potential at high doses). Emodin and anthraquinone-containing herbs are contraindicated during pregnancy (stimulant laxative effect may induce uterine contractions) and lactation (anthraquinones pass into breast milk), and should be avoided in patients with intestinal obstruction, [inflammatory](/ingredients/condition/inflammation) bowel disease, or renal insufficiency.

## Scientific Research

The body of evidence for emodin consists almost entirely of in vitro cell culture studies and in vivo rodent model experiments; as of the current literature review, no large-scale randomized controlled trials (RCTs) in human populations have been published evaluating emodin as a standalone therapeutic agent. In vitro studies have characterized antitumor effects at concentrations of 5–100 µM across multiple cancer cell lines including HepG2, PC3, A549, SW1990, and MHCC-97H, with quantified endpoints including apoptosis rates, cell cycle distribution, invasion assays, and protein expression by western blot. Animal studies in mice and rats using doses of 10–80 mg/kg administered over periods up to 12 weeks have demonstrated anti-tumor, [anti-inflammatory](/ingredients/condition/inflammation), and [immunomodulatory](/ingredients/condition/immune-support) effects without observable organ toxicity, though the translation of these doses to human equivalents remains uncertain. The overall evidence base is preliminary and largely mechanistic; the absence of pharmacokinetic data in humans, combined with low oral bioavailability (plasma emodin levels are often undetectable, with the primary circulating metabolite rhein peaking at 150–160 ng/ml via colonic bacterial conversion), represents a significant translational gap that limits clinical confidence.

## Historical & Cultural Context

Emodin's medicinal history is inseparable from that of its source plants, particularly Rheum palmatum (Chinese rhubarb), which has been documented in the Shennong Bencao Jing — one of the oldest Chinese pharmacopoeias, compiled circa 200 CE — as a purgative and blood-moving herb used to treat constipation, abdominal pain, and heat-toxin conditions. In Traditional Chinese Medicine (TCM), Da Huang (rhubarb root) preparations containing emodin were classified as bitter and cold in nature, directed to the stomach, large intestine, and liver meridians, and employed not only as laxatives but also for reducing fever, clearing toxins, and promoting blood circulation. Ayurvedic traditions similarly used rhubarb species (Revandchini) as digestive bitters and mild purgatives, and Aloe vera latex was employed across ancient Egyptian, Greek, and Arabic medicine for wound healing, constipation, and internal cleansing. European herbalists from the medieval period onward imported Chinese rhubarb root as a premium medicinal commodity, valuing it so highly that it commanded prices exceeding those of opium in some 17th and 18th century European markets.

## Synergistic Combinations

Emodin has demonstrated enhanced anticancer synergy when combined with conventional chemotherapeutic agents such as cisplatin and doxorubicin in preclinical models, likely because its BCL-2 downregulation and caspase-3 activation sensitize cancer cells to drug-induced DNA damage, lowering the effective chemotherapy dose required and potentially reducing off-target toxicity. Within anthraquinone-rich plant extracts, emodin co-occurs with rhein, aloe-emodin, and chrysophanol, and these structurally related compounds may act additively or synergistically across partially overlapping molecular targets including mTOR, p38MAPK, and MMP pathways, which is why whole rhubarb extracts have historically shown broader therapeutic activity than any single isolated constituent. Combining emodin-containing rhubarb extracts with [probiotic](/ingredients/condition/gut-health)s that harbor anthraquinone-metabolizing bacteria (e.g., Bifidobacterium and Clostridium species) may theoretically enhance the conversion of emodin to the bioavailable metabolite rhein, improving systemic exposure, though this specific combination has not yet been formally tested in clinical trials.

## Frequently Asked Questions

### What is emodin and what plants does it come from?

Emodin is a naturally occurring anthraquinone compound with the chemical formula C₁₅H₁₀O₅, characterized by a trihydroxy-methylanthraquinone scaffold. It is found primarily in the roots and rhizomes of rhubarb species (Rheum palmatum, Rheum officinale), the latex of Aloe vera, and the roots of Polygonum multiflorum (He Shou Wu), plants with long histories of use in Traditional Chinese and Ayurvedic medicine.

### Does emodin have proven anticancer effects in humans?

Currently, emodin's anticancer effects have only been demonstrated in preclinical settings — specifically in cell culture studies at concentrations of 20–100 µM and in rodent tumor models at doses of 20–80 mg/kg — with no published large-scale human clinical trials confirming these outcomes. The mechanisms are well-characterized at the molecular level, including BCL-2 suppression, caspase-3 activation, and G2/M cell cycle arrest, but until human trials are completed, clinical efficacy cannot be confirmed.

### Is emodin safe to take as a supplement?

Emodin showed no organ toxicity in mice at 20–80 mg/kg for 12 weeks, but its safety in humans has not been established through formal clinical trials. Anthraquinone compounds as a class carry regulatory genotoxicity warnings from agencies such as the European Medicines Agency, and emodin is contraindicated in pregnancy, lactation, and in individuals with intestinal obstruction, inflammatory bowel disease, or kidney impairment; long-term use without medical supervision is not advisable.

### How does emodin work as a laxative?

Emodin and related anthraquinones in rhubarb and aloe stimulate colonic peristalsis by irritating the intestinal mucosa and increasing electrolyte and fluid secretion into the bowel lumen, softening stool and accelerating transit. After oral ingestion, much of the emodin is converted by colonic bacteria into the active metabolite rhein, which reaches peak plasma levels of 150–160 ng/ml in a biphasic pattern at 3–5 hours and again at 10–11 hours post-dose, consistent with colonic microbial biotransformation driving the laxative effect.

### What is the bioavailability of emodin and how is it metabolized?

Oral bioavailability of intact emodin is poor; plasma concentrations of the parent compound are often undetectable after oral administration of emodin-containing plant extracts. The primary circulating form is the oxidative bacterial metabolite rhein, produced by colonic microbiota, which appears biphasically in plasma peaking at 150–160 ng/ml at 3–5 hours and 10–11 hours post-dose, suggesting that gut microbiome composition may significantly influence individual response to emodin-containing preparations.

### Can I get enough emodin from dietary sources like rhubarb and aloe, or do I need a supplement?

While rhubarb, aloe vera, and Polygonum multiflorum (fo-ti) naturally contain emodin, the concentrations vary significantly depending on plant part, growing conditions, and processing methods. Dietary sources provide some emodin, but clinical studies showing therapeutic effects typically use concentrated extracts or isolated emodin at doses difficult to achieve through food alone. Most people seeking emodin's documented anti-inflammatory or laxative benefits opt for standardized supplements to ensure consistent dosing.

### Does emodin interact with blood thinners, diabetes medications, or other common drugs?

Emodin may potentiate anticoagulant and antiplatelet effects due to its bioactive mechanisms, requiring caution if combined with warfarin, aspirin, or similar medications. Limited human data exists on interactions with diabetes drugs, though emodin's metabolic effects warrant monitoring in diabetic patients. Anyone taking prescription medications should consult a healthcare provider before starting emodin supplements, as most drug interaction studies remain in vitro or animal models.

### Who should avoid emodin supplements, and is it safe during pregnancy or breastfeeding?

Emodin should be avoided during pregnancy and breastfeeding due to insufficient safety data and its anthraquinone properties, which can stimulate uterine contractions and pass into breast milk. Individuals with chronic diarrhea, inflammatory bowel disease, or electrolyte imbalances should use caution, as emodin's laxative effects may worsen these conditions. Those with liver disease or taking hepatotoxic medications should consult a clinician, as emodin is metabolized hepatically and may increase burden on compromised liver function.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*